Michael W Devlin

We are a team of people who are passionate about healthcare and the technologies that allow individuals to live longer, healthier lives. Atlas5D focuses on developing new innovative ways to gather real-world information to help people stay happy and healthy by enabling them to make informed health decisions.

Ceres Nanosciences Inc. ("Ceres"​) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology. The Nanotrap® technology, coupled with existing research and clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres currently sells the Nanotrap® technology for use in a broad range of research and diagnostic applications.

We are a team of people who are passionate about healthcare and the technologies that allow individuals to live longer, healthier lives. Atlas5D focuses on developing new innovative ways to gather real-world information to help people stay happy and healthy by enabling them to make informed health decisions.

Ceres Nanosciences Inc. ("Ceres"​) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology. The Nanotrap® technology, coupled with existing research and clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres currently sells the Nanotrap® technology for use in a broad range of research and diagnostic applications.

An early stage venture capital firm we invest in companies with technology for precision medicine diagnosis. The technologies in focus have the characteristics of very high specificity and the capability to dramatically improve the choice of optimum therapy and reduce cost. Our companies will have a well-protected IP position and management with deep domain knowledge and a sense of creative thrift. Founded by Michael Devlin and Tom Miller, we are in the early stages of fund-raising but already have investments in prototypical portfolio companies. We have also recruited a team of eight operating advisors located in North America, Europe, and Asia with extremely deep domain expertise and operating experience.

Pharos ondersteunt partijen met kennis en expertise in een duurzame aanpak van de gezondheidsverschillen. In deze aanpak werkt Pharos samen met alle partijen die bij de aanpak van gezondheidsverschillen betrokken zijn zoals gemeenten, landelijke en lokale partijen in de zorg en verzekeraars.